Verrica Pharmaceuticals (VRCA) Other Non-Current Assets (2018 - 2026)
Verrica Pharmaceuticals (VRCA) posted quarterly Other Non-Current Assets of $640000.0 for Q1 2026, up 70.21% year-over-year from $376000.0 in Q1 2025, and up 70.21% quarter-over-quarter from $376000.0 in Q4 2025.
Verrica Pharmaceuticals (VRCA) Other Non-Current Assets (2018 - 2026) Analysis & Trends
Verrica Pharmaceuticals' Other Non-Current Assets history runs 9 years deep, the most recent figure standing at $640000.0 for Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 70.21% year-over-year to $640000.0; the TTM figure through Mar 2026 stood at $640000.0 (up 70.21% YoY), while the FY2025 annual figure was $376000.0, changed 0.0% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $640000.0, up from $376000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $40.0 million in Q1 2022, with the low at $221000.0 in Q3 2022.
- The 5-year median for Other Non-Current Assets is $436000.0 (2023), against an average of $2.7 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets surged 4123.86% in 2022, then sank 99.08% in 2023.
- Verrica Pharmaceuticals' Other Non-Current Assets stood at $276000.0 in 2022, then soared by 63.77% to $452000.0 in 2023, then retreated by 16.81% to $376000.0 in 2024, then changed by 0.0% to $376000.0 in 2025, then jumped by 70.21% to $640000.0 in 2026.
- Business Quant data shows VRCA's Other Non-Current Assets at $640000.0 in Q1 2026, $376000.0 in Q4 2025, and $376000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 638,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 638,000.00 |
| Mar 31, 2026 | 640,000.00 |
| Dec 31, 2025 | 376,000.00 |
| Sep 30, 2025 | 376,000.00 |
| Jun 30, 2025 | 376,000.00 |
| Mar 31, 2025 | 376,000.00 |
| Dec 31, 2024 | 376,000.00 |
| Sep 30, 2024 | 538,000.00 |
| Jun 30, 2024 | 453,000.00 |
| Mar 31, 2024 | 452,000.00 |
| Dec 31, 2023 | 452,000.00 |
| Sep 30, 2023 | 526,000.00 |
| Jun 30, 2023 | 436,000.00 |
| Mar 31, 2023 | 369,000.00 |
| Dec 31, 2022 | 276,000.00 |
| Sep 30, 2022 | 221,000.00 |
| Jun 30, 2022 | 469,000.00 |
| Mar 31, 2022 | 40.00 Mn |
| Dec 31, 2021 | 295,000.00 |
| Sep 30, 2021 | 264,000.00 |